| PI | Title | Sponsor | Status | Trial ID |
| Gerald Appel, MD | The Nephrotic Syndrome Study Network (NEPTUNE) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Enrolling | NCT01240564 |
| Gerald Appel, MD | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | Biogen Idec | Enrolling | NCT01499355 |
| Gerald Appel, MD | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis | Bristol-Myers Squibb | Enrolling | NCT01714817 |
| Gerald Appel, MD | An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients with Membranous (Class V) Lupus Nephritis | Ohio State University / Questcor Pharmaceuticals | Enrolling | NCT01926054 |
| Gerald Appel, MD | ATHENA: A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients (RG012-01) | Regulus Therapeutics, Inc. | Enrolling | NCT02136862 |
| Andrew Bomback, MD, MPH | A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | ChemoCentryx | Enrolling | NCT02222155 |
| Pietro Canetta, MD, MSc | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis | Human Genome Sciences Inc., a GSK Company
| Enrolling | NCT01639339 |
| Pietro Canetta, MD, MSc | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy, QSC01-MN-01 | Questcor Pharmaceuticals | Enrolling | NCT01386554 |
| David J. Cohen, MD | Natural History of Infection Caused by BK Virus (and other Opportunistic Viral Pathogens) in Renal and Renal-Pancreas Transplant Recipients, DMID 11-0071 | National Institutes of Health (NIH) | Enrolling | — |
| David J. Cohen, MD | Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant (ENLiST Registry) | Bristol Myers Squib | Enrolling | NCT01386359 |
| David J. Cohen, MD | Renal Allograft Tolerance Through Mixed Chimerism | Internal | Not Yet Inititated at this Site | NCT01780454 |
| Anjali Ganda, MD, MS | HDL-mediated Cholesterol Efflux in Patients with Chronic Kidney Disease | National Institutes of Health (NIH) | Enrolling | — |
| Ali Gharavi, MD | Genetic Studies of Chronic Kidney Disease | National Institutes of Health (NIH) | Enrolling | — |
| Ali Gharavi, MD | Cure Glomerulonephropathy (CureGN) | National Institutes of Health (NIH) | Enrolling | — |
| Krzysztof Kiryluk, MD, MS | Genetic Studies of Transplant Outcomes | National Institutes of Health (NIH) | Enrolling | — |
| Sumit Mohan, MD, MPH | iChoose Kidney Decision Aid for End-Stage Renal Disease Patients | Emory University | Enrolling | NCT02235571 |
| Thomas Nickolas, MD, MS | Bone Mass & Strength after Kidney Transplant | Norman S. Coplon Extramural Grant | Enrolling | NCT02224144 |
| Jai Radhakrishnan, MD, MS | Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (PKD 156-13-211) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Enrolling by Invitation | NCT02251275 |
| Jai Radhakrishnan, MD, MS | Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease (PKD 156-13-210) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not Yet Inititated at this Site | NCT02160145 |
| Maya Rao, MD | Creating a Comprehensive Nutrition Plan in Patients with Advanced Chronic Kidney Disease: a Pilot Study | Irving Institute for Clinical and Translational Research | Enrolling | — |
